CTOR: Koefisien rega marang pendapatan Citius Oncology Inc
The P/S ratio of Citius Oncology, Inc. (CTOR) reflects current dynamics, with the latest value recorded as 7.60. Experienced executives are effectively implementing innovative therapy methods. Profit growth is driven by patents for high-margin antineoplastic drugs. Development stability is maintained through the strategic outsourcing of clinical trials to external contractors under strict internal control.
Rincian metrik lan analitis perusahaan Citius Oncology, Inc (CTOR)
- rega pasar lan target rega analis:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Citius Oncology, Inc.|CTOR - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal Citius Oncology Inc|CTOR - Gunggung utang perusahaan|Rasio utang marang aset resik Citius Oncology, Inc|CTOR - Utang jangka dawa perusahaan|Utang jangka cendhak Citius Oncology|Rasio likuiditas darurat citiusonc.com
- statistik bathi lan rasio pasar:
CTOR - Bathi resik|Bathi mangsa ngarep Citius Oncology, Inc.|CTOR - Rasio rega marang bathi|Rasio prakiraan rega marang bathi Citius Oncology Inc.|CTOR - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Citius Oncology, Inc|CTOR - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Citius Oncology|CTOR - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku citiusonc.com|CTOR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham ing taun ngarep Citius Oncology, Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:citiusonc.com, CTOR
The P/S multiple compares market capitalization to revenue, allowing for an assessment of the value of each unit of sales and the identification of market anomalies. For Citius Oncology, Inc. (CTOR), which holds exclusive patented technologies in blood cancer therapy, the price-to-sales multiple reflects the potential for high asset premiums, where the stability of the chart confirms the company's fundamental resilience in the absence of effective market analogues.
Pesaing Citius Oncology, Inc.
Kapitalisasi marang pendapatan beigene.com ONC|Multiplikator P/S HALO (Halozyme)|Koefisien rega marang pendapatan Revolution Medicines Inc (RVMD)|AAPG: Kapitalisasi marang pendapatan|CG Oncology Therapeutics - Kapitalisasi marang volume dodolan|URGN: Multiplikator P/S|BCAX - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan PSNL|Multiplikator P/S Erasca Inc|Rasio rega marang pendapatan Delcath (DCTH)|Koefisien rega marang pendapatan Y-mAbs Corp|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY - Rasio rega marang pendapatan|Rega marang dodolan SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan HURA|TARA (Protara Therapeutics) - Multiplikator P/S|Kapitalisasi marang pendapatan fatetherapeutics.com (FATE)|Rasio rega marang pendapatan Aadi Bioscience Inc (WHWK)|TCRX - Rega marang dodolan|Rasio rega marang pendapatan Champions Oncology, Inc. CSBR|XBiotech Inc - Rasio rega marang pendapatan|CVM - Rasio rega marang pendapatan|Rega marang dodolan ostherapies.com|RADX: Multiplikator P/S|Multiplikator rega marang pendapatan Artiva Biotherapeutics ARTV|Kapitalisasi marang pendapatan ANL|Rega marang dodolan Veru Corporation VERU|Kapitalisasi marang pendapatan TPST (Tempest Therapeutics)|XLO (xiliotx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S RENB (Renovaro)|Koefisien rega marang pendapatan Mural Oncology PLC (MURA)|KAPA - Rasio rega marang pendapatan|OKUR (OnKure Therapeutics Inc) - Rasio kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Kapitalisasi marang pendapatan Curis|Kapitalisasi marang pendapatan APLM|Tharimmune Inc (THAR) - Koefisien rega marang pendapatan|Multiplikator P/S ADVB|Kapitalisasi marang pendapatan Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan SBFM (sunshinebiopharma.com)|XBIO - Rasio rega marang pendapatan|Rega marang dodolan Salarius Pharmaceuticals Inc|Purple Biotech Corp (PPBT) - Rasio rega marang pendapatan|American Oncology Network, Inc. - Rasio kapitalisasi pasar marang pendapatan|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Kapitalisasi marang pendapatan checkpointtx.com (CKPT)|Multiplikator P/S ELEV|Multiplikator P/S icadmed.com (ICAD)|Rasio rega marang pendapatan Ikena Oncology IKNA|NTBL: Rasio kapitalisasi marang pendapatan|Viracta - Multiplikator P/S|morphosys.com (MOR) - Kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
